Single-ventricle
1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
1 program1
PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart DiseasePhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Human BioSciencesPK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
Innovation PharmaceuticalsInspiratory muscle therapy
Clinical Trials (2)
Total enrollment: 31 patients across 2 trials
NCT06613477Human BioSciencesPK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
PK/PD of Digoxin in Infants With SVHD
Start: Oct 2024Est. completion: Apr 202624 patients
Phase 1/2Completed
Inspiratory Muscle Therapy in Subjects With Fontan Circulations
Start: Jan 2016Est. completion: Aug 20177 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.